Trials / Completed
CompletedNCT05571163
A Study to Evaluate the Relative Bioavailability of AMG 510 Administered as Tablets and as a Water Dispersion in Healthy Participants
An Open-label, Randomized, 2-Period, 2-Treatment Crossover Study to Evaluate the Relative Bioavailability of AMG 510 Administered as Tablets and as a Water Dispersion in Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 13 (actual)
- Sponsor
- Amgen · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The primary objective of the study is to evaluate the pharmacokinetics (PK) of AMG 510 administered as 8 x 120-mg tablets and as water dispersion in healthy participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AMG 510 | Tablets |
Timeline
- Start date
- 2020-03-06
- Primary completion
- 2020-06-14
- Completion
- 2020-06-14
- First posted
- 2022-10-07
- Last updated
- 2022-10-07
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05571163. Inclusion in this directory is not an endorsement.